Natera is no longer a prenatal-testing company that happens to sell an oncology assay. The second-quarter print shows Signatera, the personalized blood test that hunts leftover cancer DNA after treatment, pulling the whole franchise into a different economic category. Companion-diagnostic approval in bladder cancer and a Japanese clearance in colorectal cancer arrived in the same window as the largest sequential jump in clinical molecular residual disease units the company has ever posted. That combination is why management lifted full-year revenue guidance by $100 million at the midpoint. The investment debate is whether that volume-and-status flywheel can close the still-wide gap to reported profitability before a rich multiple demands it.
The volume story is not a rounding error on a prenatal base. Oncology tests processed rose to about 297 thousand units, more than half again the year-ago run rate, while the broader lab cleared more than one million tests for a second straight quarter. Signatera's collected price moved to about $1,275, still far below the long-horizon objective management cites. Gross margin sat near 65 percent, helped by price and lab efficiency, even as later cash collections on older claims remained a real but shrinking share of the print. The tension is simple. Unit growth is already compounding, but the price that turns those units into operating leverage is still a reimbursement project, not a finished fact.
Cash still rose in the quarter and the net loss narrowed, so the growth is no longer being purchased with an accelerating burn. Operating expense, however, still outruns gross profit because research spend on early detection and a thick clinical-trial slate is rising faster than selling costs are settling. The next several quarters resolve a narrower question than whether Signatera works in the clinic. They resolve whether sequential clinical residual-disease adds stay near recent records after a weather-distorted first-quarter base, whether new Medicare molecular-coverage filings start to lift price, and whether the patent-verdict overhang remains an appeal footnote rather than a cash event.